Semperit (SEM) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
24 Dec, 2025Executive summary
Leadership transition with new CEO Manfred Stanek, emphasizing operational excellence and strategic focus on industrial elastomers and engineered technology niches.
Achieved all strategic milestones, including full exit from glove business, realignment into two divisions (SIA and SEA), and acquisition of RICO for engineered technology.
Focus on organic growth, innovation, and readiness for market recovery, aiming to return to over EUR 1 billion in revenues.
Divisional structure confirmed as growth platform, with cost leadership in Industrial Applications and niche specialization in Engineered Applications.
Free cash flow nearly doubled to EUR 45.8 million, supporting a stable dividend proposal of EUR 0.50 per share.
Financial highlights
EBITDA increased 21.1% year-over-year to EUR 84.9 million, with margin up 2.3 percentage points to 12.5%.
Earnings after tax turned positive, from a EUR 17 million loss in 2023 to EUR 11.5 million profit in 2024.
Revenues slightly declined by 0.8% to EUR 676.6 million, with RICO consolidation offsetting lower volumes.
Operating EBITDA (adjusted) reached EUR 86.3 million, up 8% year-over-year, excluding EUR 1.5 million digitalization project costs.
Free cash flow up 74.4% to EUR 45.8 million; cash reserves at EUR 126 million.
Outlook and guidance
Operational EBITDA for 2025 expected between EUR 70 million and EUR 90 million, depending on market recovery.
CapEx planned at EUR 60 million for 2025, split between maintenance and strategic growth projects.
Targeting operating EBITDA of EUR 120 million in 2026, contingent on market support.
Challenging market conditions expected in H1 2025; recovery anticipated in H2 2025 in select regions.
Project expenses for digitalization (oneERP) expected at EUR 5 million annually.
Latest events from Semperit
- Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 202518 Mar 2026 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - Q3 2025 profit turnaround and strong order intake support a confident full-year EBITDA outlook.SEM
Q3 202517 Dec 2025 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 202526 Nov 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 202523 Nov 2025